Heparin and Derivatives for Advanced Cell Therapies |
| |
| Authors: | Sandra Laner-Plamberger Michaela Oeller Eva Rohde Katharina Schallmoser Dirk Strunk |
| |
| Affiliation: | 1.Department of Transfusion Medicine, Paracelsus Medical University of Salzburg, 5020 Salzburg, Austria; (S.L.-P.); (M.O.); (E.R.);2.Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University of Salzburg, 5020 Salzburg, Austria;3.Cell Therapy Institute, Paracelsus Medical University of Salzburg, 5020 Salzburg, Austria |
| |
| Abstract: | Heparin and its derivatives are saving thousands of human lives annually, by successfully preventing and treating thromboembolic events. Although the mode of action during anticoagulation is well studied, their influence on cell behavior is not fully understood as is the risk of bleeding and other side effects. New applications in regenerative medicine have evolved supporting production of cell-based therapeutics or as a substrate for creating functionalized matrices in biotechnology. The currently resurgent interest in heparins is related to the expected combined anti-inflammatory, anti-thrombotic and anti-viral action against COVID-19. Based on a concise summary of key biochemical and clinical data, this review summarizes the impact for manufacturing and application of cell therapeutics and highlights the need for discriminating the different heparins. |
| |
| Keywords: | heparin cell therapy regenerative medicine biomaterials human platelet lysate extracellular vesicles |
|
|
